Mic drop.

In case you didn’t read to the end of the manuscript on the EF-14 trial of TTF for GBM, we're throwing down Roger Stupp’s closing paragraph: “These findings are in contrast to the more than [*]23[*] randomized trials conducted over the last decade that have evaluated novel agents or intensified treatment strategies (eg, dose-dense temozolomide, cilengitide, nimotuzumab, bevacizumab, and rindopepimut) for treatment of patients with newly diagnosed glioblastoma and have failed to demonstrate improved survival. Innovative treatments for glioblastoma are needed.”